Clearmind Medicine CEO to Present at the 8th Annual Dawson James Conference

Clearmind Medicine Inc., a biotech company focused on developing psychedelic-derived therapeutics, has announced that its CEO, Dr. Adi Zuloff-Shani, will be presenting at the 8th Annual Dawson James Conference. The conference will take place on October 12th, 2023, at the Wyndam Grand Jupiter in Jupiter, Florida.

The presentation by Dr. Zuloff-Shani will be held in Track One – Preserve Ballroom C at 5:00 PM ET. The event provides an opportunity for Clearmind Medicine to showcase its innovative approach to solving under-treated health problems using psychedelic-derived compounds.

The Dawson James Conference specializes in capital raising for small and microcap growth companies, primarily in the Life Science/Health Care, Technology, Clean tech, and Consumer sectors. With offices in Boca Raton, New York, Maryland, and New Jersey, Dawson James Securities offers a full range of investment banking services.

Clearmind Medicine is dedicated to discovering and developing novel psychedelic-derived therapeutics to address widespread and underserved health issues, including alcohol use disorder. The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements. Clearmind’s intellectual property portfolio currently consists of fifteen patent families, with plans to acquire additional patents as needed.

Investors and members of the investor community will have the opportunity to engage in one-on-one meetings with Clearmind Medicine’s management during the conference. To request a meeting, interested parties can contact CMND@crescendo-ir.com.

For more information about Clearmind Medicine Inc., its mission, and its stock listings on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange, please visit their website at www.clearmindmedicine.com or contact their Investor Relations team at invest@clearmindmedicine.com or (604) 260-1566.